[ExpireDate]: 25.06.2021
[ExternalReference]: 2021-575560
[FtsReference]: 2021-011393
[FtsS09F02ContractNotice]
[Information]
[FtsS09F02ContractNotice]
[NoticeContract]
[Section1]: [Ca]
I.1)
[NameAddressContact]
NHS England - Specialised Commissioning)
80 London Road
London
SE1 6LH
UK
[AddressEmail]:
lisa.innes1@nhs.net
[Nutscode]:
UK -
UNITED KINGDOM
[UrlGeneral]:
https://www.england.nhs.uk/commissioning/spec-services/
[UrlBuyerprofile]:
https://www.ardengemcsu.nhs.uk/
I.3)
[InfoTendering]
[AddressObtainDocs]:
https://uk.eu-supply.com/login.asp?B=AGCSU&target=[AddressFurtherinfo]
[AsContactsAbove]:
[AddressSendTendersRequest]
[AddressSendTenders]:
https://uk.eu-supply.com/login.asp?B=AGCSU&target=
[AddressSendTendersRequest]
[AddressToAbove]
I.4)
[CaType]
[MaintypePublicbody]
I.5)
[Mainactivity]
[MainactivHealth]
[Section2]: [Object]
II.1)
[QuantityScopeContract]
II.1.1)
[TitleContract]
NHS England Spec. Commissioning - Thrombotic Thrombocytopenic Purpura (TTP) all ages (up to 8 Lots)
[Fileref]:
NHSSC-TPP-2021- NHS England
II.1.2)
[CpvMain]
85100000
-
II.1.3)
[TypeContract]
[Services]
II.1.4)
[DescrShort]
Thrombotic Thrombocytopenic Purpura (TTP) is a serious blood disorder that results in blood clots forming in small blood vessels throughout the body. It affects the kidneys, heart and brain. If a patient is treated outside a specialist centre, mortality is 50%; in a specialist centre, it is 20%. There is also an appreciable acute morbidity, particularly in neurological disorders.
The Condition can be difficult to diagnose because initial presentation can be non-specific and this is a very rare disease. Rapid treatment is essential for optimal outcomes and includes plasma exchange and a range of drugs. This disease primarily affects Adults. Children are treated in paediatric haematology centres and are outside the scope of this process.
The Condition can be difficult to diagnose because initial presentation can be non-specific and this is a very rare disease. Rapid treatment is essential for optimal outcomes and includes plasma exchange and a range of drugs. This disease primarily affects Adults. Children are treated in paediatric haematology centres and are outside the scope of this process.
II.1.5)
[ValueMagnitudeEstimatedTotal]
[ValueExclVat]: 54943200.00
GBP
II.1.6)
[LotsInfo]
[DivisionLots]:
[Yes]
[LotsSubmittedFor]
[LotsAll]
[LotsMaxAwarded]:
1
II.2)
[Description]
II.2.1)
[TitleContract]
Thrombotic Thrombocytopenic Purpura (TTP) – London and the South East (Kent, Surrey, East & West Sussex)
[LotNumber]:
1
II.2.2)
[CpvAdditional]
85100000
-
85000000
-
II.2.3)
[PlacePerformance]
[Nutscode]:
UKJ4 -
Kent
[Nutscode]:
UKJ2 -
Surrey, East and West Sussex
[Nutscode]:
UKI -
LONDON
[MainsiteplaceWorksDelivery]:
London and the South East (Kent, Surrey, East & West Sussex)
II.2.4)
[DescrProcurement]
Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to bid for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
There are patient flows to London from all over the South East. Commissioners have considered establishing one specialist provider for all of London and the South East and this is the default commissioner position.
Commissioners will consider bids for the South East (Thames Valley and Hampshire and Isle of Wight areas - (Lot 2)), to facilitate patient choice and to reduce the requirement to travel for providers who meet the criteria in the service specification, in the technical questionnaire and who are willing to work within a Clinical Partnership with the successful bidder for the London and South East Lot (Lot 1).
The contracting term for these services will be for a period of up to 4 years.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to bid for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
There are patient flows to London from all over the South East. Commissioners have considered establishing one specialist provider for all of London and the South East and this is the default commissioner position.
Commissioners will consider bids for the South East (Thames Valley and Hampshire and Isle of Wight areas - (Lot 2)), to facilitate patient choice and to reduce the requirement to travel for providers who meet the criteria in the service specification, in the technical questionnaire and who are willing to work within a Clinical Partnership with the successful bidder for the London and South East Lot (Lot 1).
The contracting term for these services will be for a period of up to 4 years.
II.2.5)
[AwardCriteria]
[AwardCriteriaBelow]
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section K : Skills and competences
/
[Weighting]:
20
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section L: Managing access and treatment pathway
/
[Weighting]:
42
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section M: Mobilisation
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section N: Education and service continuity
/
[Weighting]:
6
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section O: Clinical outcomes and governance
/
[Weighting]:
7
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section P: Patient satisfaction and patient group
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
: Section Q: Networks and leadership
/
[Weighting]:
5
[Price]
-
[Weighting]:
0
II.2.6)
[ValueMagnitudeEstimated]
[ValueExclVat]: 20589200.00
GBP
II.2.7)
[DurationContractFrameworkDps]
[DurationMonths]:
48
[RenewalsSubject]:
[No]
II.2.10)
[VariantsInfo]
[VariantsAccepted]:
[No]
II.2.11)
[OptionsInfo]
[Options]:
[No]
II.2.13)
[EuProgrInfo]
[EuProgrRelated]:
[No]
II.2.14)
[InfoAdditional]
Please note that Lots may have changed from previous publications.
II.2)
[Description]
II.2.1)
[TitleContract]
Thrombotic Thrombocytopenic Purpura (TTP) - South East (Thames Valley, Hampshire and the Isle of Wight)
[LotNumber]:
2
II.2.2)
[CpvAdditional]
85000000
-
85100000
-
II.2.3)
[PlacePerformance]
[Nutscode]:
UKJ -
SOUTH EAST (ENGLAND)
[MainsiteplaceWorksDelivery]:
South East (Thames Valley, Hampshire and the Isle of Wight)
II.2.4)
[DescrProcurement]
Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years.
II.2.5)
[AwardCriteria]
[AwardCriteriaBelow]
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section K : Skills and competences
/
[Weighting]:
20
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section L: Managing access and treatment pathway
/
[Weighting]:
42
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section M: Mobilisation
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section N: Education and service continuity
/
[Weighting]:
6
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section O: Clinical outcomes and governance
/
[Weighting]:
7
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section P: Patient satisfaction and patient group
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section Q: Networks and leadership
/
[Weighting]:
5
[Price]
-
[Weighting]:
0
II.2.6)
[ValueMagnitudeEstimated]
[ValueExclVat]: 4173800.00
GBP
II.2.7)
[DurationContractFrameworkDps]
[DurationMonths]:
48
[RenewalsSubject]:
[No]
II.2.10)
[VariantsInfo]
[VariantsAccepted]:
[No]
II.2.11)
[OptionsInfo]
[Options]:
[No]
II.2.13)
[EuProgrInfo]
[EuProgrRelated]:
[No]
II.2.14)
[InfoAdditional]
Please note that Lots may have changed from previous publications.
II.2)
[Description]
II.2.1)
[TitleContract]
Thrombotic Thrombocytopenic Purpura (TTP) - West Midlands
[LotNumber]:
3
II.2.2)
[CpvAdditional]
85000000
-
85100000
-
II.2.3)
[PlacePerformance]
[Nutscode]:
UKG -
WEST MIDLANDS (ENGLAND)
[MainsiteplaceWorksDelivery]:
West Midlands
II.2.4)
[DescrProcurement]
Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years
II.2.5)
[AwardCriteria]
[AwardCriteriaBelow]
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section K : Skills and competences
/
[Weighting]:
20
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section L: Managing access and treatment pathway
/
[Weighting]:
42
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section M: Mobilisation
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section N: Education and service continuity
/
[Weighting]:
6
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section O: Clinical outcomes and governance
/
[Weighting]:
7
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section P: Patient satisfaction and patient group
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section Q: Networks and leadership
/
[Weighting]:
5
[Price]
-
[Weighting]:
0
II.2.6)
[ValueMagnitudeEstimated]
[ValueExclVat]: 7633000.00
GBP
II.2.7)
[DurationContractFrameworkDps]
[DurationMonths]:
48
[RenewalsSubject]:
[No]
II.2.10)
[VariantsInfo]
[VariantsAccepted]:
[No]
II.2.11)
[OptionsInfo]
[Options]:
[No]
II.2.13)
[EuProgrInfo]
[EuProgrRelated]:
[No]
II.2.14)
[InfoAdditional]
Please note that Lots may have changed from previous publications.
II.2)
[Description]
II.2.1)
[TitleContract]
Thrombotic Thrombocytopenic Purpura (TTP) - East Midlands
[LotNumber]:
4
II.2.2)
[CpvAdditional]
85000000
-
85100000
-
II.2.3)
[PlacePerformance]
[Nutscode]:
UKF -
EAST MIDLANDS (ENGLAND)
[MainsiteplaceWorksDelivery]:
East Midlands
II.2.4)
[DescrProcurement]
Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres centre in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres centre in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years.
II.2.5)
[AwardCriteria]
[AwardCriteriaBelow]
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section K : Skills and competences
/
[Weighting]:
20
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section L: Managing access and treatment pathway
/
[Weighting]:
42
[AwardCriterionQuality]
-
[AwardCriterionName]:
: Section M: Mobilisation
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section N: Education and service continuity
/
[Weighting]:
6
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section O: Clinical outcomes and governance
/
[Weighting]:
7
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section P: Patient satisfaction and patient group
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section Q: Networks and leadership
/
[Weighting]:
5
[Price]
-
[Weighting]:
0
II.2.6)
[ValueMagnitudeEstimated]
[ValueExclVat]: 4041100.00
GBP
II.2.7)
[DurationContractFrameworkDps]
[DurationMonths]:
48
[RenewalsSubject]:
[No]
II.2.10)
[VariantsInfo]
[VariantsAccepted]:
[No]
II.2.11)
[OptionsInfo]
[Options]:
[No]
II.2.13)
[EuProgrInfo]
[EuProgrRelated]:
[No]
II.2.14)
[InfoAdditional]
Please note that Lots may have changed from previous publications.
II.2)
[Description]
II.2.1)
[TitleContract]
Thrombotic Thrombocytopenic Purpura (TTP) - East of England
[LotNumber]:
5
II.2.2)
[CpvAdditional]
85000000
-
85100000
-
II.2.3)
[PlacePerformance]
[Nutscode]:
UKH -
EAST OF ENGLAND
[MainsiteplaceWorksDelivery]:
East of England
II.2.4)
[DescrProcurement]
Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years.
II.2.5)
[AwardCriteria]
[AwardCriteriaBelow]
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section K : Skills and competences
/
[Weighting]:
20
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section L: Managing access and treatment pathway
/
[Weighting]:
42
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section M: Mobilisation
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section N: Education and service continuity
/
[Weighting]:
6
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section O: Clinical outcomes and governance
/
[Weighting]:
7
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section P: Patient satisfaction and patient group
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section Q: Networks and leadership
/
[Weighting]:
5
[Price]
-
[Weighting]:
0
II.2.6)
[ValueMagnitudeEstimated]
[ValueExclVat]: 4017500.00
GBP
II.2.7)
[DurationContractFrameworkDps]
[DurationMonths]:
48
[RenewalsSubject]:
[No]
II.2.10)
[VariantsInfo]
[VariantsAccepted]:
[No]
II.2.11)
[OptionsInfo]
[Options]:
[No]
II.2.13)
[EuProgrInfo]
[EuProgrRelated]:
[No]
II.2.14)
[InfoAdditional]
Please note that Lots may have changed from previous publications.
II.2)
[Description]
II.2.1)
[TitleContract]
Thrombotic Thrombocytopenic Purpura (TTP) - North East
[LotNumber]:
6
II.2.2)
[CpvAdditional]
85000000
-
85100000
-
II.2.3)
[PlacePerformance]
[Nutscode]:
UKC -
NORTH EAST (ENGLAND)
[MainsiteplaceWorksDelivery]:
North East
II.2.4)
[DescrProcurement]
Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years.
II.2.5)
[AwardCriteria]
[AwardCriteriaBelow]
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section K : Skills and competences
/
[Weighting]:
20
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section L: Managing access and treatment pathway
/
[Weighting]:
42
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section M: Mobilisation
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section N: Education and service continuity
/
[Weighting]:
6
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section O: Clinical outcomes and governance
/
[Weighting]:
7
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section P: Patient satisfaction and patient group
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section Q: Networks and leadership
/
[Weighting]:
5
[Price]
-
[Weighting]:
0
II.2.6)
[ValueMagnitudeEstimated]
[ValueExclVat]: 40002800.00
GBP
II.2.7)
[DurationContractFrameworkDps]
[DurationMonths]:
48
[RenewalsSubject]:
[No]
II.2.10)
[VariantsInfo]
[VariantsAccepted]:
[No]
II.2.11)
[OptionsInfo]
[Options]:
[No]
II.2.13)
[EuProgrInfo]
[EuProgrRelated]:
[No]
II.2.14)
[InfoAdditional]
Please note that Lots may have changed from previous publications.
II.2)
[Description]
II.2.1)
[TitleContract]
Thrombotic Thrombocytopenic Purpura (TTP) - Yorkshire and the Humber
[LotNumber]:
7
II.2.2)
[CpvAdditional]
85000000
-
85100000
-
II.2.3)
[PlacePerformance]
[Nutscode]:
UKE -
YORKSHIRE AND THE HUMBER
[MainsiteplaceWorksDelivery]:
Yorkshire and the Humber
II.2.4)
[DescrProcurement]
Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years
II.2.5)
[AwardCriteria]
[AwardCriteriaBelow]
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section K : Skills and competences
/
[Weighting]:
20
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section L: Managing access and treatment pathway
/
[Weighting]:
42
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section M: Mobilisation
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section N: Education and service continuity
/
[Weighting]:
6
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section O: Clinical outcomes and governance
/
[Weighting]:
7
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section P: Patient satisfaction and patient group
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section Q: Networks and leadership
/
[Weighting]:
5
[Price]
-
[Weighting]:
0
II.2.6)
[ValueMagnitudeEstimated]
[ValueExclVat]: 4851400.00
GBP
II.2.7)
[DurationContractFrameworkDps]
[DurationMonths]:
48
[RenewalsSubject]:
[No]
II.2.10)
[VariantsInfo]
[VariantsAccepted]:
[No]
II.2.11)
[OptionsInfo]
[Options]:
[No]
II.2.13)
[EuProgrInfo]
[EuProgrRelated]:
[No]
II.2.14)
[InfoAdditional]
Please note that Lots may have changed from previous publications.
II.2)
[Description]
II.2.1)
[TitleContract]
Thrombotic Thrombocytopenic Purpura (TTP) - South West
[LotNumber]:
8
II.2.2)
[CpvAdditional]
85000000
-
85100000
-
II.2.3)
[PlacePerformance]
[Nutscode]:
UKK -
SOUTH WEST (ENGLAND)
II.2.4)
[DescrProcurement]
Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years
There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.
NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting bids for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.
The contracting term for these services will be for a period of up to 4 years
II.2.5)
[AwardCriteria]
[AwardCriteriaBelow]
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section K : Skills and competences
/
[Weighting]:
20
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section L: Managing access and treatment pathway
/
[Weighting]:
42
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section M: Mobilisation
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section N: Education and service continuity
/
[Weighting]:
6
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section O: Clinical outcomes and governance
/
[Weighting]:
7
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section P: Patient satisfaction and patient group
/
[Weighting]:
10
[AwardCriterionQuality]
-
[AwardCriterionName]:
Section Q: Networks and leadership
/
[Weighting]:
5
[Price]
-
[Weighting]:
0
II.2.6)
[ValueMagnitudeEstimated]
[ValueExclVat]: 5634400.00
GBP
II.2.7)
[DurationContractFrameworkDps]
[DurationMonths]:
48
[RenewalsSubject]:
[No]
II.2.10)
[VariantsInfo]
[VariantsAccepted]:
[No]
II.2.11)
[OptionsInfo]
[Options]:
[No]
II.2.13)
[EuProgrInfo]
[EuProgrRelated]:
[No]
II.2.14)
[InfoAdditional]
Please note that Lots may have changed from previous publications.
[Section3]: [InfoLegal]
III.1)
[ConditionsParticip]
III.1.3)
[TechnicalCapacity]
[InfoEvaluatingWethRequir]:
All technical capacity and its evaluation criteria are specified within the tender documentation.
III.2)
[ConditionsContract]
[Section4]: [Procedure]
IV.1)
[Description]
IV.1.1)
[TypeProcedure]
[ProctypeOpen]
IV.1.8)
[GpaInfo]
[GpaCovered]
: [Yes]
IV.2)
[InfoAdmin]
IV.2.1)
[PubPrevious]
[NumberOj]: 2021/S 000-006895
IV.2.2)
[LimitReceiptTendersReqPart]
[Date]:
25.06.2021
[Time]:
17:00
IV.2.4)
[LanguagesAllowed]
[Language_EN]
IV.2.7)
[OpeningConditions]
[Date]:
25.06.2021
[Time]:
17:00
[Section6]: [InfoComplement]
VI.1)
[RecurrenceInfo]
[RecurrentProcurement]:
[No]
VI.3)
[InfoAdditional]
In response to a recommendation from the Prescribed Specialised Services Advisory Group in 2014, NHS England developed a service model that aimed to balance the high levels of multi-disciplinary expertise required to treat patients with TTP with the requirement for patients to be treated rapidly to have optimal outcomes. NHS England undertook a public consultation on the draft service specification, which closed in October 2018. The consultation documents are still available on the NHS England website at this link:
Consultation on service specifications for thrombotic thrombocytopenic purpura (TTP) for all ages - NHS England - Citizen Space.
The model of delivery is to offer in-patient care within a specialist TTP centre, Patients with TTP require lifelong monitoring and follow up to manage relapse. Shared care is possible, based on the preference of the patient. Specialist TTP centres are required to undertake a clinical leadership, proactive education and outreach service to hospitals within their region to improve the identification of patients with TTP and the timely referral of patients to the specialist TTP centres. Specialist TTP centres are required to establish robust clinical partnerships with paediatric haematology centres to provide support in relation to the treatment of children and to agree a transition policy.
There are patient flows to London from all over the South East. Commissioners have considered establishing one provider for all of London and the South East and this is the default Commissioner position. Commissioners will consider bids for the South East (Thames Valley and Hampshire and Isle of Wight areas, (Lot 2)) to facilitate patient choice and to reduce the requirement to travel for providers who meet the criteria in the service specification, in the technical questionnaire and who are willing to work within a Clinical Partnership with the successful bidder for the London and South East Lot (Lot 1).
This will support effective care and improve local patient access to the service whilst ensuring availability of clinical expertise as appropriate.
To register your interest in these services please follow this link https://uk.eu-supply.com/ctm/supplier/publictenders?B=UK and either login or register on EU Supply and search from ID number 43998. All Bidders are asked to complete the general Qualification and Technical questions and the Lot specific Qualification and Technical Questions for the Lots they are applying for. Bidders may apply for more than one Lot, but will only be awarded a maximum of one Lot. Please refer to the Process Selection Process Overview documents for further details.
Consultation on service specifications for thrombotic thrombocytopenic purpura (TTP) for all ages - NHS England - Citizen Space.
The model of delivery is to offer in-patient care within a specialist TTP centre, Patients with TTP require lifelong monitoring and follow up to manage relapse. Shared care is possible, based on the preference of the patient. Specialist TTP centres are required to undertake a clinical leadership, proactive education and outreach service to hospitals within their region to improve the identification of patients with TTP and the timely referral of patients to the specialist TTP centres. Specialist TTP centres are required to establish robust clinical partnerships with paediatric haematology centres to provide support in relation to the treatment of children and to agree a transition policy.
There are patient flows to London from all over the South East. Commissioners have considered establishing one provider for all of London and the South East and this is the default Commissioner position. Commissioners will consider bids for the South East (Thames Valley and Hampshire and Isle of Wight areas, (Lot 2)) to facilitate patient choice and to reduce the requirement to travel for providers who meet the criteria in the service specification, in the technical questionnaire and who are willing to work within a Clinical Partnership with the successful bidder for the London and South East Lot (Lot 1).
This will support effective care and improve local patient access to the service whilst ensuring availability of clinical expertise as appropriate.
To register your interest in these services please follow this link https://uk.eu-supply.com/ctm/supplier/publictenders?B=UK and either login or register on EU Supply and search from ID number 43998. All Bidders are asked to complete the general Qualification and Technical questions and the Lot specific Qualification and Technical Questions for the Lots they are applying for. Bidders may apply for more than one Lot, but will only be awarded a maximum of one Lot. Please refer to the Process Selection Process Overview documents for further details.
VI.4)
[AppealsProcedure]
VI.4.1)
[AppealsBody]
Arden & GEM Commissioning Support Unit
Derby
DE1 3QT
UK
VI.4.2)
[MediationBody]
Arden & GEM Commissioning Support Unit
Derby
DE1 3QT
UK
VI.4.4)
[AppealsInfo]
Arden & GEM Commissioning Support Unit
Derby
DE1 3QT
UK